17 Tabeeva, G.R. Amelin, A.V. Akhmadeeva, L.R. Danilov, A.B. Doronina, O.B. Koreshkina, M.I. Kurushina, O.V. Osipova, V.V. Sergeev, A.V. Filatova, E.G. Shestel, E.A. Anti-CGRP therapy Headache Migraine Monoclonal antibodies Targeted therapy WOS 2018 2018-08-13 Migraine is the third most common disease in the world. The overall prevalence of migraine in the Russian Federation is estimated at 20% with an estimated global prevalence of 14.7%. Migraine affects mostly people of working age and has a significant negative impact on the quality of life, the level of adaptation, ability to work, social functioning. Migraine represents a significant social and economic burden for patients and society as a whole. A team of national experts on migraine offers a program to prioritize quality of management of patients with headache. © Team of authors, 2018. https://repo.bashgmu.ru/publication/722 https://repo.bashgmu.ru/files/834